Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

MNG1181

669682fe-8529-5d53-8a89-a5569b5f962f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.295
  • PANCREAS_BETA_CELLS+0.174
  • BILE_ACID_METABOLISM+0.102
  • PROTEIN_SECRETION+0.072
  • TGF_BETA_SIGNALING+0.067
  • UV_RESPONSE_DN+0.066
  • PEROXISOME+0.058
  • MYC_TARGETS_V1+0.055
  • NOTCH_SIGNALING+0.040
  • FATTY_ACID_METABOLISM+0.009

Top 10 suppressed

  • IL6_JAK_STAT3_SIGNALING-0.467
  • HYPOXIA-0.408
  • COMPLEMENT-0.382
  • MITOTIC_SPINDLE-0.368
  • COAGULATION-0.359
  • TNFA_SIGNALING_VIA_NFKB-0.355
  • APOPTOSIS-0.342
  • INTERFERON_ALPHA_RESPONSE-0.333
  • INFLAMMATORY_RESPONSE-0.332
  • GLYCOLYSIS-0.324

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_SDCNP7MW
medullo-epn-umap@date-based
EPNEPN Tumor0.876
2SRR8942973
bladder-landscape@3
0.865
3TCGA-37-4129-01A-01R-1100-07
lung-landscapes@6
cohortSC0.859
4SRR8943008
bladder-landscape@3
0.852
5SRR10900001
melanoma-umap@29
0.851
6SAMN03290937
melanoma-umap@29
0.847
7C3N-03420
lung-landscapes@6
cohortA10.842
8SRR8613727
breast-umap@18
D0.841
9R247
bladder-landscape@3
0.840
10DRR168565
bladder-landscape@3
0.839

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.295Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.174Cobimetinib— uncovered
BILE_ACID_METABOLISM0.102Inavolisib— uncovered
PROTEIN_SECRETION0.072Remibrutinib— uncovered
TGF_BETA_SIGNALING0.067Inavolisib— uncovered
UV_RESPONSE_DN0.066Inavolisib— uncovered
PEROXISOME0.058Idelalisib— uncovered
MYC_TARGETS_V10.055Inavolisib— uncovered
NOTCH_SIGNALING0.040Inavolisib— uncovered
FATTY_ACID_METABOLISM0.009Inavolisib— uncovered